

Disclosure of a received transparency notification in accordance with article 14 of the act of 2 May 2007 on disclosure of large shareholdings

Updated – see footnote (February 3, 2026)

Liège, Belgium – February 2, 2026 – 09:30 PM CET – Regulated Information – In accordance with article 14 of the Act of 2 May 2007 on disclosure of large shareholdings, Hyloris Pharmaceuticals SA (“Hyloris”) (Euronext Brussels: HYL), the specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that it has received the following transparency notification:

1. Summary of the notification

On February 2, 2026, Hyloris has received a transparency notification dated January 20, 2026, indicating that Bart Versluys, through Scorpiaux BV and Versluys Bouwgroep NV, following an acquisition of shares on January 9, 2026, now holds 7.57% of the voting rights in Hyloris. He has thus crossed the threshold of 7.5% as laid down in Article 12 of Hyloris’s articles of association.

2. Content of the notification

The information contained in the notification is the following:

<i>Reason for the notification:</i>	Acquisition or disposal of voting securities or voting rights
<i>Notification by:</i>	A parent undertaking or a controlling person
<i>Persons subject to the notification requirement:</i>	<ul style="list-style-type: none">- Bart Versluys- Scorpiaux BV (Address: Blinckaertlaan 4, 8300 Knokke-Heist)- Versluys Bouwgroep NV (Address: Zandvoordestraat 465, 8400 Oostende)
<i>Date on which the threshold is crossed:</i>	January 9, 2026
<i>Threshold that is crossed (in %):</i>	7.5
<i>Denominator:</i>	28,000,374



Notified details:

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Versluys Bart	0	0		0.00%	
Scorpiaux BV	1,727,739 ⁽¹⁾	2,081,445		7.43%	
Versluys Bouwgroep NV		38,329		0.14%	
Subtotal	1,727,739 ⁽¹⁾	2,119,774		7.57%	
	TOTAL	2,119,774	0	7.57%	0.00%

⁽¹⁾ Note to updated press release: the current transparency notification of Bart Versluys dated January 20, 2026, mentioned 1,717,739 voting rights, although the previous transparency notification of Bart Versluys dated July 2, 2020, mentioned 1,727,739 voting rights.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
-	-	-	-	-	-	-	-
	TOTAL	-	-	-	-	-	-

TOTAL (A & B)				# of voting rights	% of voting rights
				2,119,774	7.57%

Full chain of controlled undertakings through which the holding is effectively held, if applicable:

Bart Versluys controls Scorpiaux BV
Bart Versluys controls Versluys Invest as 50% shareholder.
Versluys Invest is 100%-shareholder of Versluys Bouwgroep NV



About Hyloris Pharmaceuticals

Hyloris is the specialty biopharma company focused on innovating, reinventing, and optimizing existing medications through reformulation and repurposing to address important healthcare needs and deliver meaningful improvements for patients, healthcare professionals and payors. The Company's development strategy primarily focuses on leveraging established regulatory pathways, such as the FDA's 505(b)(2) pathway in the U.S or equivalent regulatory frameworks in other regions which are specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This approach can reduce the clinical and regulatory burden required for market entry, and significantly shorten the development timelines, leading to reduced costs and risks. Hyloris has announced a broad development portfolio of 28 products, including 25 value-added medicines of which two products are currently in early stages of commercialization in collaboration with commercial partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. In addition to its core strategic focus, the Company has two high barrier generic products approved in the U.S. and one high-barrier generic product in development. Beyond its announced portfolio, Hyloris has initiated several additional internal early-stage development activities, bringing the total pipeline to more than 30 products and product candidates, and continues to evaluate further product opportunities to support future growth. Hyloris is based in Liège, Belgium and since 2020 listed on Euronext Brussels (EBR: HYL).

For more information, please visit www.hyloris.com and follow us on [LinkedIn](#).

Contacts Hyloris Pharmaceuticals :

Ann De Jaeger, CLO

legal representative of Impact WITH Empathy BV

Ann.dejaeger@hyloris.com

32 (0)475 20 13 44 - 32 (0)4 346 02 07

Stijn Van Rompay, CEO

legal representative of SVR Management BV

Stijn.vanrompay@hyloris.com

32 (0)4 346 02 07

Christophe Maréchal, CFO

Représentant légal de CMM&C SRL

Christophe.marechal@hyloris.com

+32 (0)4 346 02 07

Disclaimer and forward-looking statements

Hyloris means "high yield, lower risk", which relates to the 505(b)(2) regulatory pathway for product approval on which the Company focuses, but in no way relates or applies to an investment in the Shares. Certain statements in this press release are "forward-looking statements." These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

